Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
Active, not recruiting · NCT02872025 · Registry updated 2025-01-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) | Neoplasms by Histologic Type, Neoplasms, Ductal, Lobular, and Medullary, adenocarcinoma, breast carcinoma in situ, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, neoplasm | Active, not recruiting | Early phase 1 | 2025-01-30 | NCT02872025 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Laura Esserman | 1 |
| Merck Sharp & Dohme LLC | 650 |
| ModernaTX, Inc. | 41 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of California, San Francisco | San Francisco | United States | 294 |